AB Science Granted U.S. Patent for Masitinib in Prostate Cancer
AB Science announced that it has received a patent acceptance notification from the U.S. Patent Office for a patent covering the use of masitinib in the treatment of hormone-resistant metastatic prostate cancer. This intellectual property protection adds to the coverage already granted in Europe.
U.S. Patent Approval for Masitinib in mCRPC Treatment
The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance (NOA) for a patent related to the methods of treating hormone-resistant metastatic prostate cancer (mCRPC) with masitinib. Once granted, this new medical use patent will ensure intellectual property protection until May 2042. This protection complements the coverage already granted in Europe (EP4175639). Equivalent patent applications have also been filed in other major international markets.
Patent Specifically Protects Masitinib for mCRPC Treatment
The patent specifically protects masitinib for the treatment of mCRPC in a sub-population of patients with low metastatic burden, measured by alkaline phosphatase levels at inclusion. This population corresponds to the results of the AB12003 study and the ongoing clinical development program of masitinib in this indication. Masitinib is positioned in combination with docetaxel as a treatment for patients eligible for chemotherapy, administered after treatment of hormone-sensitive metastatic prostate cancer.
